Skip to main content
Literatur
1.
Zurück zum Zitat Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403.CrossRefPubMed Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403.CrossRefPubMed
2.
Zurück zum Zitat Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, et al. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117(6):1296–301.CrossRefPubMed Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, et al. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117(6):1296–301.CrossRefPubMed
3.
Zurück zum Zitat Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73.CrossRefPubMed Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73.CrossRefPubMed
4.
Zurück zum Zitat Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26(6):1230–7.CrossRefPubMed Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26(6):1230–7.CrossRefPubMed
5.
Zurück zum Zitat Ueda S, Satoh T, Gotoh M, Gao L, Doi T. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist. 2015;20(5):493–4.CrossRefPubMedPubMedCentral Ueda S, Satoh T, Gotoh M, Gao L, Doi T. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist. 2015;20(5):493–4.CrossRefPubMedPubMedCentral
Metadaten
Titel
Wound Healing Failure Following Venous Access Chest Port Placement Associated with Ramucirumab Therapy
verfasst von
Chenyang Zhan
Amy R. Deipolyi
Joseph P. Erinjeri
Publikationsdatum
19.07.2017
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 11/2017
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-017-1752-8

Weitere Artikel der Ausgabe 11/2017

CardioVascular and Interventional Radiology 11/2017 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.